双参数MRI联合前列腺特异性抗原密度分析:在穿刺前诊断Gleason评分7分及以上前列腺癌中的作用
纳入68例连续接受穿刺前双参数MRI及穿刺活检的患者,以系统穿刺与靶向穿刺病理为参考标准,评估双参数MRI定性(PI-RADSv2、mPI-RADSv2)与定量参数(肿瘤平均ADC、第10百分位ADC、平均ADCR、第10百分位ADCR)及PSA、PSAD对Gleason评分7分及以上前列腺癌的诊断效能及联合模型价值。
要点
- 双参数MRI各参数诊断GS≥7前列腺癌的AUC为0.763~0.838,两两比较均无显著差异(P>0.05)。
- PSAD的AUC为0.745,高于PSA的0.650(P=0.017)。
- 双参数MRI联合PSAD的6个模型AUC为0.806~0.880,各模型间比较均无显著差异(P>0.05)。
核心结论
- 穿刺前双参数MRI联合PSAD分析有助于识别Gleason评分7分及以上前列腺癌。
研究设计与样本
- 连续纳入68例接受穿刺前双参数MRI及穿刺活检的患者,以系统穿刺与靶向穿刺病理结果为参考标准。
诊断标准与关键数值
- GS≥7前列腺癌发生率45.6%(31/68)。
- 双参数MRI参数诊断GS≥7前列腺癌的AUC:PI-RADSv2为0.816,mPI-RADSv2为0.838,肿瘤平均ADC为0.820,肿瘤第10百分位ADC为0.823,平均ADCR为0.780,第10百分位ADCR为0.763,各参数两两比较P>0.05。
- PSA与PSAD诊断GS≥7前列腺癌的AUC:PSA为0.650,PSAD为0.745,PSA vs PSAD的P=0.017。
- 联合模型诊断活检GS≥7前列腺癌的AUC:模型1(PSAD+PI-RADSv2)为0.860,模型2(PSAD+mPI-RADSv2)为0.880,模型3(PSAD+平均ADC)为0.837,模型4(PSAD+第10百分位ADC)为0.844,模型5(PSAD+平均ADCR)为0.811,模型6(PSAD+第10百分位ADCR)为0.806,各模型间比较P>0.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of our study was to investigate the diagnostic performance of prebiopsy biparametric MRI (bpMRI) and prostate-specific antigen density (PSAD) for Gleason score (GS) 7 or greater prostate cancer (PCa).
MATERIALS AND METHODS: Sixty-eight consecutive patients who underwent prebiopsy bpMRI and biopsy were included. Pathologic results of systemic and targeted biopsies were the reference standard. Qualitative analyses comprised Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) and modified PI-RADSv2 (mPI-RADSv2). Quantitative analyses comprised mean apparent diffusion coefficient (ADC) of tumor, 10th percentile ADC of tumor, mean ADC ratio (ADCR) between benign tissues and PCa, and 10th percentile ADCR between benign tissues and PCa. The AUCs of the following combined models for GS 7 or greater PCa were investigated: model 1, PSAD and PI-RADSv2; model 2, PSAD and mPI-RADSv2; model 3, PSAD and mean ADC; model 4, PSAD and 10th percentile ADC; model 5, PSAD and mean ADCR; and model 6, PSAD and 10th percentile ADCR.
RESULTS: The rate of GS 7 or greater PCa was 45.6% (31/68). AUCs of bpMRI parameters were 0.816 for PI-RADSv2, 0.838 for mPI-RADSv2, 0.820 for mean ADC, 0.823 for 10th percentile ADC, 0.780 for mean ADCR, and 0.763 for 10th percentile ADCR (p > 0.05 in all comparisons), whereas AUCs of prostate-specific antigen (PSA)-based parameters were 0.650 for PSA and 0.745 for PSAD (PSA vs PSAD, p = 0.017). AUCs of the combined models from 1 to 6 were 0.860, 0.880, 0.837, 0.844, 0.811, and 0.806, respectively, for biopsy GS 7 or greater PCa (p > 0.05 in all comparisons).
CONCLUSION: Combined analysis of prebiopsy bpMRI and PSAD is useful for identifying GS 7 or greater PCa.
引用
- Lee SJ, Oh YT, Jung DC, et al. Combined Analysis of Biparametric MRI and Prostate-Specific Antigen Density: Role in the Prebiopsy Diagnosis of Gleason Score 7 or Greater Prostate Cancer. AJR Am J Roentgenol. 2018. PMID: 30016148. doi:10.2214/AJR.17.19253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。